Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing

Credit: CC0 Public Domain

A study by researchers at Mayo Clinic published this week in the Journal of Clinical Oncology suggests that all women with a breast cancer diagnosis under the age of 66 be offered germline genetic testing to determine if they have a gene mutation known to increase the risk of developing other cancers and cancers among blood relatives. Current guidelines from the National Comprehensive Cancer Network (NCCN) recommend germline testing for all women diagnosed with breast cancer under the age of 46 regardless of their family history and breast cancer subtype.

"There is considerable confusion regarding the best method for selecting who may benefit from hereditary cancer from among all women diagnosed with cancer," says Fergus Couch, Ph.D., a breast cancer researcher at Mayo Clinic. "The NCCN has very specific guidelines for who may benefit from genetic testing based on the age of diagnosis and family history of certain cancers while the American Society of Breast Surgeons (ASBrS ) recommends testing all women with breast cancer."

For their study, Dr. Couch and his colleagues evaluated all known breast cancer predisposition genes in a Mayo Clinic breast cancer registry and showed that NCCN guidelines overlooked approximately 30% of patients with genetic mutations known to increase the risk of developing breast cancer. Based on this information

Dr. Couch and his colleagues recommend increasing the age for genetic testing to all women diagnosed with breast cancer under the age of 66 irrespective of of cancer . "This change would help identify 98% of women with BRCA1 and BRCA2 mutations, and more than 90% of women with mutations in other predisposition genes, while avoiding testing of 20% of all breast cancers," says Dr. Couch.

He says this approach may also result in a reduced burden on the genetic services needed for women receiving testing.

"We were surprised to find that the NCCN guidelines missed approximately 30% of mutation carriers in breast cancer predisposition genes," says Siddhartha Yadav, M.B.B.S., a medical oncologist and first author of the study.

"A few recent studies have demonstrated that NCCN guidelines could miss a substantial number of mutation carriers. However, these studies included several genes that are not typically associated with breast cancer risk. Our study was appropriately restricted to nine breast cancer predisposition genes with clear management guidelines."

Dr. Couch says it was encouraging to note that by simply changing the age cutoff for germline genetic testing in women with breast cancer, rather than other more complicated approaches, it should be possible to identify the majority of mutation carriers. In women diagnosed with over the age of 65, the study supports the use of NCCN guidelines to decide who should undergo germline genetic testing. The overall result is that many more and their family members can benefit from knowing that they are at increased risk of .

Journal information: Journal of Clinical Oncology

©2020 Mayo Foundation for Medical Education and Research
Distributed by Tribune Content Agency, LLC.

Citation: Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing (2020, February 21) retrieved 2 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Study supports germline testing for all metastatic breast cancer patients


Feedback to editors